The global virology market size accounted for USD 2.86 billion in 2024, grew to USD 3 billion in 2025 and is projected to surpass around USD 4.70 billion by 2034, representing a healthy CAGR of 5.10% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Virology Market
5.1. COVID-19 Landscape: Virology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Virology Market, By Product Type
8.1. Virology Market, by Product Type, 2024-2034
8.1.1 Diagnosing Test
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Viral Infection Controlling Methods
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Antiviral Chemotherapy
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Interferons
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Virology Market, By Application
9.1. Virology Market, by Application, 2024-2034
9.1.1. Skin and Soft Tissue Infections
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Respiratory Tract Infections
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. GI Tract Infections
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Urinary Tract Infections
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Eye Infections
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Sexually Transmitted Diseases
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Perinatal Infections
9.1.7.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Virology Market, By End User
10.1. Virology Market, by End User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Laboratories
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Diagnostic Centers
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Blood Banks
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Pharmacies
10.1.6.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Virology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
Chapter 12. Company Profiles
12.1. GlaxoSmithKline plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abbott Laboratories
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Boehringer Ingelheim Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck and Co. Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis International AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Siemens
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Johnson & Johnson
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AstraZeneca AB
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Roche
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Trinity Biotech
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample